2-(3-Methyl-1,2,4-oxadiazol-5-yl)benzoic acid → (RS)-1-(2-Benzothiazol-2-ylmethylpiperidin-1-yl)-1-[2-(3-methyl-[1,2,4]oxadiazol-5-yl)phenyl]-methanone
반응식
[NH:1]1[CH2:6][CH2:5][CH2:4][CH2:3][CH:2]1[CH2:7][C:8]1[S:9][C:10]2[CH:16]=[CH:15][CH:14]=[CH:13][C:11]=2[N:12]=1.[CH3:17][C:18]1[N:22]=[C:21]([C:23]2[CH:31]=[CH:30][CH:29]=[CH:28][C:24]=2[C:25](O)=[O:26])[O:20][N:19]=1>>[S:9]1[C:10]2[CH:16]=[CH:15][CH:14]=[CH:13][C:11]=2[N:12]=[C:8]1[CH2:7][CH:2]1[CH2:3][CH2:4][CH2:5][CH2:6][N:1]1[C:25]([C:24]1[CH:28]=[CH:29][CH:30]=[CH:31][C:23]=1[C:21]1[O:20][N:19]=[C:18]([CH3:17])[N:22]=1)=[O:26]참가 물질
3
실험 절차
The title compound (0.170 g) was prepared from 2-piperidin-2-ylmethyl-benzothiazole, D30 (0.135 g), and 2-(3-methyl-[1,2,4]oxadiazol-5-yl)benzoic acid (0.126 g) using the procedure described in Example 60.
출처 및 근거
- ORD 기록
- ord-576f158c8e384773b85fdec12655b816
- 출처 데이터셋
- uspto-grants-2011_04